Brief: Marksans Pharma Says U.S. FDA Inspection Of Goa Facility Resulted In Form 483 With 8 Observations
07/03/2019 08:33
March 7 (Reuters) - Marksans Pharma Ltd MARK.NS :
* U.S. FDA HAS CONCLUDED INSPECTION OF COMPANY'S GOA
FACILITY
* SAYS INSPECTION RESULTING IN A FORM 483 WITH EIGHT
OBSERVATIONS
* NONE OF THE OBSERVATIONS ARE CONSIDERED EITHER CRITICAL OR
REPETITIVE IN NATURE
Source text: https://goo.gl/vPmmzH
Further company coverage: MARK.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg